Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070530 | 0.89 | RET (0.44) | RETGRM2 | |
| SCHEMBL20149611 | 0.88 | RET (0.46) | RETHCRTR1HCRTR2DAOGRM2 | |
| SCHEMBL20148641 | 0.87 | RET (0.49) | RETHCRTR1HCRTR2DAOGRM2 | |
| SCHEMBL18390927 | 0.84 | RET (0.48) | RET | |
| SCHEMBL21158879 | 0.81 | RET (0.47) | RET | |
| SCHEMBL20069808 | 0.80 | HCRTR1 (0.41) | RETHCRTR1HCRTR2 | |
| SCHEMBL22811997 | 0.79 | CYP11B1 (0.42) | RET | |
| SCHEMBL20149634 | 0.78 | RET (0.44) | RETGRM2 | |
| SCHEMBL22812025 | 0.77 | ALDH1A1 (0.48) | RET | |
| SCHEMBL22031240 | 0.77 | RET (0.43) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523301-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
| WO-2018071447-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885HCRTR1 2431/4885HCRTR2 3399/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885HCRTR1 2431/4885HCRTR2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.